ENDRA Life Sciences Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T

What the company is saying

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Analysis

The announcement is a factual regulatory filing disclosing that NDRA has received a notice of delisting or failure to satisfy a continued listing rule or standard. There are no forward-looking statements, projections, or claims of future benefit; the only claim is the occurrence of the filing itself, which is already realised. No language in the announcement attempts to inflate or reframe the event positively, nor is there any attempt to downplay the seriousness of the notice. There is no mention of capital outlay, remedial plans, or timelines for resolution. The gap between narrative and evidence is nonexistent, as the filing is strictly administrative and contains no promotional or exaggerated language.

Announcement summary

NDRA filed a notice on 2026-04-21 regarding delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. The filing is identified as Item 3.01. The Accession Number is 0001213900-26-045885 and the file size is 194 KB. This announcement is significant for investors as it indicates a potential change in NDRA's listing status.

Disagree with this article?